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Introduction
In a developing country, where infection, malnutrition and 
HIV infection cause an enormous burden of  childhood 
illnesses, cancer is, for many, not a priority. It is reported 
that globally 80% of  the children who develop cancer have 
no or poor access to cancer treatment1 but childhood cancer 
is often curable and every child needs care, be it curative or 
palliative.
In this paper we describe the children’s cancer unit (called 
Sobo ward) in the Queen Elizabeth Central Hospital 
(QECH); some of  the common cancers and treatments 
given and their outcome. This is written with the intention to 
encourage early referral of  children who need investigation 
for possible malignancy and to highlight what positive results 
can be achieved.   
The ward
Children with cancer have been treated in QECH since 1964. 
In 1997 a separate paediatric oncology ward was opened and 
dedicated to the treatment of  children with cancer. It has 
17 beds. It is staffed by 5 nurses, a play lady, a social worker, 
1 clinical officer, and daily attendance of  a paediatrician. A 
paediatric surgeon visits twice weekly. 
Medical treatment (drugs and investigations) is free and the 
hospital supplies two meals a day for each patient and one 
guardian. Patients come mainly from the southern region of  
Malawi, but some are from the North or Central regions and 
some have travelled from Mozambique.
Facilities, supportive care
Facilities have steadily improved over the years. We can 
do full blood counts, blood cultures,  electrolytes, X rays, 
ultrasound scans, CT-scans and MRI scans.  A range of  
chemotherapeutic drugs is available. Good supportive 
care is essential when giving chemotherapy to patients. 
These supportive care facilities are first line and second 
line antibiotics, antifungal therapy, topical and oral antiviral 
drugs, blood products, nutritional support, and adequate 
pain control. The chemotherapy protocols in general are 
less toxic than protocols used in the West to avoid treatment 
related morbidity and mortality.
Common problems at presentation
Children with cancer in Malawi often present late with 
advanced disease. Access to health care, transport problems, 
lack of  knowledge of  the disease and possible treatment all 
play a role. Many children remain undiagnosed. The incidence 
of  cancer in children <15 years in Europe is around 140 per 
million children.2 Transferring this figure to Malawi with a 
population of  6.5 million children below the age of  15 years 
would mean that we would expect an incidence of  around 
900 cases of  childhood  cancer per year in Malawi. 
Malnutrition - nutritional support
We found that 55 % (70 of  128) of  children with cancer 
admitted to the Queen Elizabeth Central Hospital are 
acutely malnourished at admission. This is caused by the 
high prevalence of  undernutrition in Malawi, combined 
with the often delayed presentation with a malignant disease. 
Weight for height is not a good assessment of  malnutrition 
in these children as large (often abdominal) masses mask the 
loss of  body weight. In our study, weight for height detected 
malnutrition in only 17.2 % (22 of  128) of  children yet 
55% were malnourished using other criteria such as MUAC 
(mid upper arm circumference), skinfold thickness or arm 
muscle area AMA.3 Nutritional support is essential during 
treatment and we provide chiponde, a locally made ready to 
use therapeutic peanut butter-based food which is protein 
and energy rich. Naso gastric tube feeding is rarely practised 
as parents are reluctant to accept it.
Social support – failure to complete treatment
Failure to complete paediatric cancer treatment is a common 
problem in developing countries.4 The treatment may take 
a few weeks, sometimes even months. During this time 
the child and his/her guardian usually stay in the hospital. 
Financial costs (transport, food during their stay in the 
hospital) are important concerns for parents. The absence 
from home (work on the field, income generating activities) 
is another concern.5
Parents in Malawi are highly motivated to continue with 
treatment if  they think that it will cure their child. The 
diagnosis of  cancer is usually made on admission to hospital 
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and causes fear of  recurrence and death. Guardians are 
reluctant to ask health personnel questions about recurrence 
and outcome. They worry that taking frequent blood samples 
will weaken their child. The side effects of  the chemotherapy, 
such as vomiting, are seen as a proof  of  efficacy.5 
A play lady is present on the ward every working day of  the 
week. She has some toys and drawing material. This is greatly 
appreciated by the children as they are away from home and 
their play mates for a long time. 
Patients
Currently about 160 new patients are admitted each year. 
Burkitt’s lymphoma is the most common cancer in malaria 
endemic parts of  Africa6 and more than half  of  the patients 
have Burkitt’s lymphoma. About 10 – 15 a year have Wilms’ 
tumour,  10 have other lymphomas and approximately 
20 have AIDS related Kaposi’s sarcoma.3 Patients with 
retinoblastoma are seen first by eye specialists. Patients with 
osteosarcoma are often first seen by orthopaedic surgeons. 
(Table 1)
Table I. Clinical diagnoses of children admitted to Sobo ward QECH 
January 1st 2007 – January 1st 2008   (n=136)
Clinical diagnosis Number % of total FNA 
confirmed
(Number)
Burkitt’s lymphoma 82 60.2 52
Lymphoma (not BL) 10 7.3 2
Wilms’ Tumour 11 8 6
Neuroblastoma 6 4.4 0*
Rhabdomyosarcoma 4 2.9 2
Germ cell tumour 2 1.4 1
Hepatocellular carcinoma 3 2.2 1
Osteosarcoma 4 2.9 2  
Leukaemia 1 0.7 0  
Other (or unknown) 7 5.1 3
Brain tumour 2 1.4 0  
Retinoblastoma 4 2.9 4
FNA - fine need aspirates
* Two fine needle aspirates (FNAs) showed small blue round cells.
Burkitt’s lymphoma
Burkitt’s lymphoma (BL) is a very rapidly growing tumour. 
Children commonly present with a mass in the jaw, orbital 
socket or abdomen. They may present with weakness in the 
legs, paraplegia and urinary incontinence, caused by a tumour 
involving or compressing the spinal cord.7 This is a condition 
which needs urgent treatment. With  treatment, we often see 
complete recovery of  the neurological signs. 
In well resourced countries patients with BL have a 1 year 
survival of  > 90 % when treated with very intense protocols 
requiring intense supportive care.8 Over the last 10 years 
a local protocol has been developed for the treatment of  
patients with Burkitt’s Lymphoma. The previous protocol, 
modified from a protocol (called the LMB protocol) showed 
an unacceptably high mortality rate related to treatment. 
Eleven of  42 (26 %) children died of  treatment related 
toxicity, such as sepsis with neutropenia.8 The protocol 
has been modified over several years and is now a shorter, 
cheaper protocol with limited toxicity.8
The treatment for children with Burkitt’s lymphoma (all 
stages) consists of  intravenous cyclophosphamide 40 mg/
kg on day 1 and oral cyclophosphamide 60 mg/kg on day 
8, 18 and 28.  Intrathecal hydrocortisone (12.5 mg) and 
methotrexate (12.5 mg) are also given at each treatment 
cycle. The 1 year event free survival of  this protocol is 48 % 
, The treatment related mortality is around 5 %. 9
Rescue treatment (3 weekly courses of  high dose 
cyclophosphamide (60mg/kg) and vincristine (1.5mg/m 
2IV) for 28 cases of  relapse (n=20) or primary resistance 
(n= 8) led to a disease free survival of  > one year (406-712 
days) in a further one third of  all relapsed cases.9
Wilms tumour
Worldwide Wilms tumour has an incidence of  around 8 per 
million children below the age of  15 years.10,11 The common 
presentation is a child of  about three years old, with a 
painless, firm mass in the flank.
In QECH, about 15 new patients with Wilms tumour per 
year are seen. Many children present with very large tumours 
weighing over 2kgs with local or distant spread. Patients with 
Wilms tumour in the West have a 5 year disease free survival 
greater than 80 %.12 A previous retrospective review in the 
QECH showed a survival of  20 – 50 % with 30 % lost to 
follow up.13 This was when only vincristine was available 
for preoperative chemotherapy. We now have all the drugs 
that are used in protocols designed by SIOP (International 
Society of  Paediatric Oncology) and use these protocols 
which have been  modified to the situation in Malawi. The 
preoperative treatment for localized disease is four weeks 
of  vincristine and actinomycin; for metastatic disease 
(usually chest, sometimes liver) doxorubicin is added and 
the treatment period prolonged to 6 weeks. Postoperative 
treatment depends on the stage and grade of  the tumour at 
surgery and is usually a total of  26 weeks, with intervals of  4 
weeks when patients can go home.
A boy with Wilm’s tumour
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We have yet to see if  this treatment has lead to improved 
disease free survival.
Kaposi’s sarcoma
AIDS related Kaposi’s sarcoma is a common disease in Sub 
Saharan Africa, both in adults and in children.14 It used to be 
a very rare cause of  generalised lymphadenopathy in young 
children before the HIV epidemic emerged. In 10 years 
from 1967-76 only 11 cases were reported in Malawi.15,16 
The incidence has increased over the last 10 -20 years with 
the rise of  prevalence of  HIV infected children.17,18 KS can 
clinically present in several ways. It commonly causes skin 
lesions on the feet, legs, face (nose) and genitalia. It can cause 
painful and functionally disturbing lymphoedema especially 
in the lower extremities, but also in the face and genitalia. KS 
often presents with lesions in the oral cavity which can be 
painful and hamper food intake. It may cause gastrointestinal 
- or (life threatening) pulmonary disease.19 Kaposi’s sarcoma 
is a stage IV AIDS defining disease and qualifies a child in 
Malawi to start anti retroviral therapy (ART). ARTs are the 
best treatment for KS but in extensive, symptomatic KS 
additional treatment is needed. We have been giving children 
injections of  vincristine (weekly for 3 weeks then fortnightly 
for 3 courses) as additional treatment. We have shown that 
thalidomide is an effective palliative therapy in widespread 
KS.20 We are planning to compare different treatment options 
in the future to be assess how best to treat these children 
with minimal toxicity and improved quality of  life.
Other cancers
Acute leukaemia is the most common cancer to be diagnosed 
in well resourced countries and yet it is rarely diagnosed in 
Malawi. This is probably because the symptoms (anaemia, 
fever) resemble the clinical picture of  malaria. Besides this, 
when left untreated patients with leukaemia may die within a 
relatively short period of  time (of  weeks or a few months). Many 
other children present with other tumours such as Hodgkin’s 
lymphoma, non Hodgkin’s non Burkitt’s B cell lymphomas, 
retinoblastoma, osteosarcoma, rhabdomyosarcoma, 
hepatocellular carcinoma and neuroblastoma.17 Some are 
curable; many require symptomatic care and management.
Palliative care
Even if  not all children can be cured it is still important 
that we give adequate and holistic care to all children with 
cancer and to their families. There is much that can be done 
to give symptomatic relief, emotional and psychological and 
spiritual support.  Many of  the children with non-Wilms 
solid tumours presenting with advanced stage disease have a 
poor prognosis. Good palliative care including adequate pain 
control is essential. The Umodzi paediatric palliative care 
team do rounds on the ward every day and home visits when 
necessary. A description of  their activities appears elsewhere 
in this journal.
Conclusion
Malignant disease in children can be treated. BL can be cured 
in 60 % of  cases. We anticipate improved long term survival 
with the Wilm’s tumour protocol now in use in the QECH. 
All children with suspected cancer need evaluation, diagnosis 
and a proper treatment and management plan which is best 
undertaken by an experienced team. Delay in referral and 
treatment are detrimental to the child and the family. We 
have shown that for the most common tumours found in 
Malawian children good results can be obtained with simple 
and safe protocols.
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